查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1869760

美国气喘药物市场规模、份额和趋势分析报告：按药物类别、医疗设备类型、给药途径、产品和细分市场预测（2025-2033 年）

U.S. Asthma Therapeutics Market Size, Share & Trends Analysis Report By Drug Class (Anti-inflammatory, Bronchodilators), By Device Type (Inhalers, Nebulizers), By Route of Administration (Oral, Inhaled), By Product, And Segment Forecasts, 2025 - 2033
出版日期: | 出版商: Grand View Research | 英文 100 Pages | 商品交期: 2-10个工作天内

价格

市场规模与趋势：

据估计，美国气喘药物市场在 2024 年的价值为 130 亿美元，预计到 2033 年将达到 192 亿美元。

预计从 2025 年到 2033 年，气喘市场将以 4.5% 的复合年增长率成长。随着美国气喘患者人数的增加，对有效治疗方法（包括前沿和有前景的治疗方法）的需求也日益增长。

受气喘病例不断增加的推动，美国气喘药物市场呈现稳定成长态势。根据美国肺臟协会统计，美国有超过2500万人患有气喘，其中约5%至10%被诊断为重度气喘。这凸显了对更有效、更有针对性的治疗方法的迫切需求。儘管目前已有多种治疗方法，但许多患者仍频繁遭受气喘发作的困扰，这也暴露出现有药物的限制。为此，製药公司正加大投入，研发能够提供更有针对性、更有效解决方案的先进治疗方法。

2023年2月，安进和Astra Zeneca宣布，TedSpire获得美国食品药物管理局（FDA）核准，用于治疗12岁以上重度气喘患者。该药物已核准在美国使用预预填充笔自我给药。此外，该药物还在美国、日本、欧盟和其他国家核准。

精准医疗和个人化治疗方案的日益普及正在显着改变美国的气喘治疗模式。随着医疗保健朝着更个人化的方向发展，人们对生物标记和基因谱分析的兴趣日益浓厚，希望利用它们来有效指导治疗决策。这种转变使医生能够为每位患者确定气喘的真正病因，并选择最有效的治疗方法。此外，人工智慧 (AI) 和数据分析正被整合到临床实践中。这种整合提高了治疗监测的准确性和诊断精度。这些临床和技术进步不仅改善了治疗效果，也为新的药物创新创造了机会，有望推动美国气喘治疗市场持续创新主导成长。

目录

第一章调查方法和范围

第二章执行摘要

第三章：美国气喘药物市场的趋势与展望

  • 市场体系展望
    • 母市场
    • 子公司市场
  • 市场动态
    • 市场驱动因素分析
    • 市场限制因素分析
    • 市场机会分析
    • 市场问题分析
  • 美国气喘药物市场分析工具
    • 产业分析—波特五力分析
    • PESTEL 分析
    • 法律规范

第四章美国气喘药物市场：药物类别估算与趋势分析

  • 细分仪表板
  • 美国气喘药物市场：药物类别差异分析
  • 美国气喘药物市场规模及趋势分析（依药物类别划分，2021-2033 年）
  • 消炎（药）
  • 支气管扩张剂
  • 联合疗法

第五章美国气喘药物市场：器械类型估算与趋势分析

  • 细分仪表板
  • 美国气喘药物市场：器材类型差异分析
  • 美国气喘药物市场规模及趋势分析（依器材类型划分），2021-2033年
  • 吸入器
  • 喷雾器

第六章：美国气喘药物市场：产品估算与趋势分析

  • 细分仪表板
  • 美国气喘治疗市场（依产品划分）
  • 美国气喘药物市场规模及趋势分析（依产品划分，2021-2033 年）
  • 干粉
  • 计量喷雾型
  • 缓雾

第七章美国气喘药物市场：给药途径估算与趋势分析

  • 细分仪表板
  • 美国气喘药物市场：给药途径差异分析
  • 美国气喘药物市场规模及趋势分析（依给药途径划分，2021-2033 年）
    • 口服
    • 吸入
    • 静脉

第八章 竞争情势

  • 市场参与企业分类
  • 企业市场分析/堆图分析
  • 公司简介
    • Teva Pharmaceuticals Industries Ltd.
    • GSK plc
    • Merck &Co. Inc.
    • F. Hoffmann-La Roche Ltd
    • AstraZeneca
    • Boehringer Ingelheim International GmbH
    • Sanofi
    • Koninklijke Philips NV
    • Covis Pharma
    • Pfizer
    • Regeneron
    • Amgen
Product Code: GVR-4-68040-778-4

Market Size & Trends:

The U.S. asthma therapeutics market size was estimated at USD 13.00 billion in 2024 and is projected to reach USD 19.20 billion by 2033, growing at a CAGR of 4.5% from 2025 to 2033. The rising number of asthma patients in the U.S. has led to a growing demand for effective therapies, including some of the most advanced and promising treatment options.

The U.S. asthma therapeutics market is experiencing steady growth, driven by a rising number of asthma cases. According to the American Lung Association, over 25 million people in the U.S. are living with asthma, and approximately 5-10% of them have severe asthma, highlighting the urgent need for more effective and targeted treatment options.Although various therapies are available, many patients continue to experience frequent asthma attacks, highlighting the limitations of current medications. In response, pharmaceutical companies invest in developing advanced therapies that offer targeted and more effective solutions.

In February 2023, Amgen and AstraZeneca announced that the U.S. FDA approved TEZSPIRE for patients aged 12 years and older suffering from severe asthma. It has been approved for self-administration in the U.S. with a new prefilled pen. The product is also approved in the U.S., Japan, the EU, and other countries.

The increasing emphasis on precision medicine and patient-specific treatment plans is notably transforming asthma care markedly in the U.S. There is increasing interest in biomarkers and genetic profiling to effectively guide therapy decisions as healthcare shifts toward a more individualized approach. The changing scenario lets doctors spot the true sources of asthma for each patient and then choose the treatments that have the greatest effect. In addition, artificial intelligence and data analytics are being integrated into clinical practice. This integration improves diagnostic accuracy in addition to monitoring treatment. These particular clinical and technological advancements are not only enhancing therapeutic outcomes. Still, they are also creating new opportunities for pharmaceutical innovation, positioning the U.S. asthma therapeutics market for sustained, innovation-driven growth.

U.S. Asthma Therapeutics Market Report Segmentation

This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the U.S. asthma therapeutics market report based on drug class, device type, product, route of administration.

  • Drug Class Outlook (Revenue, USD Billion, 2021 - 2033)
  • Anti- inflammatory
  • Bronchodilators
  • Combination therapy
  • Device Type Outlook (Revenue, USD Billion, 2021 - 2033)
  • Inhalers
  • Nebulizers
  • Product Outlook (Revenue, USD Billion, 2021 - 2033)
  • Dry Powder
  • Metered Dose
  • Soft Mist
  • Route of Administration Outlook (Revenue, USD Billion, 2021 - 2033)
  • Oral
  • Inhaled
  • Intravenous

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Research Methodology
  • 1.3. Information Procurement
    • 1.3.1. Purchased Database
    • 1.3.2. GVR's Internal Database
    • 1.3.3. Secondary Sources
    • 1.3.4. Primary Research
  • 1.4. Information/Data Analysis
  • 1.5. Market Formulation & Visualization
  • 1.6. Data Validation & Publishing
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis
    • 1.7.2. Regional Market: CAGR Calculation
  • 1.8. List of Secondary Sources

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. U.S. Asthma Therapeutics Market Variable Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market
    • 3.1.2. Ancillary Market
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
    • 3.2.3. Market Opportunity Analysis
    • 3.2.4. Market Challenge Analysis
  • 3.3. U.S. Asthma Therapeutics Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Bargaining power of suppliers
      • 3.3.1.2. Bargaining power of buyers
      • 3.3.1.3. Threat of substitution
      • 3.3.1.4. Threat of new entrants
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political & Legal landscape
      • 3.3.2.2. Economic and Social landscape
      • 3.3.2.3. Technological landscape
      • 3.3.2.4. Environmental landscape
    • 3.3.3. Regulatory Framework

Chapter 4. U.S. Asthma Therapeutics Market: Drug Class Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. U.S. Asthma Therapeutics Market: Drug Class Movement Analysis
  • 4.3. U.S. Asthma Therapeutics Market Size & Trend Analysis, by Drug Class, 2021 to 2033 (USD Billion)
  • 4.4. Anti-inflammatory
    • 4.4.1. Anti-inflammatory Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 4.5. Bronchodilators
    • 4.5.1. Bronchodilators Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 4.6. Combine Therapy
    • 4.6.1. Combine Therapy Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Billion)

Chapter 5. U.S. Asthma Therapeutics Market: Device Type Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. U.S. Asthma Therapeutics Market: Device Type Movement Analysis
  • 5.3. U.S. Asthma Therapeutics Market Size & Trend Analysis, by Device Type, 2021 to 2033 (USD Billion)
  • 5.4. Inhalers
    • 5.4.1. Inhalers Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 5.5. Nebulizers
    • 5.5.1. Nebulizers Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Billion)

Chapter 6. U.S. Asthma Therapeutics Market: Product Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. U.S. Asthma Therapeutics Market by Product
  • 6.3. U.S. Asthma Therapeutics Market Size & Trend Analysis, by Product, 2021 to 2033 (USD Billion)
  • 6.4. Dry Powder
    • 6.4.1. Dry Powder Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 6.5. Metered Dose
    • 6.5.1. Metered Dose Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 6.6. Soft Mist
    • 6.6.1. Soft Mist Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Billion)

Chapter 7. U.S. Asthma Therapeutics Market: Route of Administration Estimates & Trend Analysis

  • 7.1. Segment Dashboard
  • 7.2. U.S. Asthma Therapeutics Market: By Route of Administration Movement Analysis
  • 7.3. U.S. Asthma Therapeutics Market Size & Trend Analysis, by Route of Administration, 2021 to 2033 (USD Billion)
    • 7.3.1. Oral
      • 7.3.1.1. Oral Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 7.3.2. Inhaled
      • 7.3.2.1. Inhaled Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 7.3.3. intravenous
      • 7.3.3.1. Intravenous Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Billion)

Chapter 8. Competitive Landscape

  • 8.1. Market Participant Categorization
  • 8.2. Company Market Position Analysis/ Heap Map Analysis
  • 8.3. Company Profiles
    • 8.3.1. Teva Pharmaceuticals Industries Ltd.
      • 8.3.1.1. Participant's Overview
      • 8.3.1.2. Financial Performance
      • 8.3.1.3. Application Benchmarking
      • 8.3.1.4. Strategic Initiatives
    • 8.3.2. GSK plc
      • 8.3.2.1. Participant's Overview
      • 8.3.2.2. Financial Performance
      • 8.3.2.3. Application Benchmarking
      • 8.3.2.4. Strategic Initiatives
    • 8.3.3. Merck & Co. Inc.
      • 8.3.3.1. Participant's Overview
      • 8.3.3.2. Financial Performance
      • 8.3.3.3. Product Benchmarking
      • 8.3.3.4. Strategic Initiatives
    • 8.3.4. F. Hoffmann-La Roche Ltd
      • 8.3.4.1. Participant's Overview
      • 8.3.4.2. Financial Performance
      • 8.3.4.3. Product Benchmarking
      • 8.3.4.4. Strategic Initiatives
    • 8.3.5. AstraZeneca
      • 8.3.5.1. Participant's Overview
      • 8.3.5.2. Financial Performance
      • 8.3.5.3. Product Benchmarking
      • 8.3.5.4. Strategic Initiatives
    • 8.3.6. Boehringer Ingelheim International GmbH
      • 8.3.6.1. Participant's Overview
      • 8.3.6.2. Financial Performance
      • 8.3.6.3. Product Benchmarking
      • 8.3.6.4. Strategic Initiatives
    • 8.3.7. Sanofi
      • 8.3.7.1. Participant's Overview
      • 8.3.7.2. Financial Performance
      • 8.3.7.3. Product Benchmarking
      • 8.3.7.4. Strategic Initiatives
    • 8.3.8. Koninklijke Philips N.V.
      • 8.3.8.1. Participant's Overview
      • 8.3.8.2. Financial Performance
      • 8.3.8.3. Product Benchmarking
      • 8.3.8.4. Strategic Initiatives
    • 8.3.9. Covis Pharma
      • 8.3.9.1. Participant's Overview
      • 8.3.9.2. Financial Performance
      • 8.3.9.3. Product Benchmarking
      • 8.3.9.4. Strategic Initiatives
    • 8.3.10. Pfizer
      • 8.3.10.1. Participant's Overview
      • 8.3.10.2. Financial Performance
      • 8.3.10.3. Product Benchmarking
      • 8.3.10.4. Strategic Initiatives
    • 8.3.11. Regeneron
      • 8.3.11.1. Participant's Overview
      • 8.3.11.2. Financial Performance
      • 8.3.11.3. Product Benchmarking
      • 8.3.11.4. Strategic Initiatives
    • 8.3.12. Amgen
      • 8.3.12.1. Participant's Overview
      • 8.3.12.2. Financial Performance
      • 8.3.12.3. Product Benchmarking
      • 8.3.12.4. Strategic Initiatives

List of Tables

  • Table 1 List of Secondary Sources
  • Table 2 U.S. Asthma Therapeutics Market, by Drug Class, 2021 - 2033 (USD Billion)
  • Table 3 U.S. Asthma Therapeutics Market, by Device Type, 2021 - 2033 (USD Billion)
  • Table 4 U.S. Asthma Therapeutics Market, by Product, 2021 - 2033 (USD Billion)
  • Table 5 U.S. Asthma Therapeutics Market, by Route of Administration, 2021 - 2033 (USD Billion)

List of Figures

  • Fig. 1 Market Segmentation
  • Fig. 2 Market Research Process
  • Fig. 3 Information Procurement
  • Fig. 4 Primary Research Pattern
  • Fig. 5 Market Research Approaches
  • Fig. 6 Value Chain-Based Sizing & Forecasting
  • Fig. 7 QFD Modelling for Market Share Assessment
  • Fig. 8 Market Formulation & Validation
  • Fig. 9 U.S. Asthma Therapeutics Market Revenue, 2021-2033 (USD Billion)
  • Fig. 10 U.S. Asthma Therapeutics Market Snapshot
  • Fig. 11 U.S. Asthma Therapeutics Market Driver Impact
  • Fig. 12 U.S. Asthma Therapeutics Market Restraint Impact
  • Fig. 13 U.S. Asthma Therapeutics Product Key Takeaways (USD Billion)
  • Fig. 14 U.S. Asthma Therapeutics Market: Product Movement Analysis
  • Fig. 15 Drug Class Market, 2021 - 2033 (USD Billion)
  • Fig. 16 Anti-inflammatory Market, 2021 - 2033 (USD Billion)
  • Fig. 17 Bronchodilators Market, 2021 - 2033 (USD Billion)
  • Fig. 18 Combination Therapy Market, 2021 - 2033 (USD Billion)
  • Fig. 19 U.S. Asthma Therapeutics Device Type Key Takeaways (USD Billion)
  • Fig. 20 U.S. Asthma Therapeutics Market: Device Type Movement Analysis
  • Fig. 21 Inhalers Market, 2021 - 2033 (USD Billion)
  • Fig. 22 Nebulizers Market, 2021 - 2033 (USD Billion)
  • Fig. 23 U.S. Asthma Therapeutics Market: Product Movement Analysis
  • Fig. 24 Dry Powder Market, 2021 - 2033 (USD Billion)
  • Fig. 25 Metered Dose Market, 2021 - 2033 (USD Billion)
  • Fig. 26 Soft Mist Market, 2021 - 2033 (USD Billion)
  • Fig. 27 U.S. Asthma Therapeutics Market Route of Administration Key Takeaways (USD Billion)
  • Fig. 28 U.S. Asthma Therapeutics Market: Route of Administration Movement Analysis
  • Fig. 29 Oral Market, 2021 - 2033 (USD Billion)
  • Fig. 30 Inhaled Market, 2021 - 2033 (USD Billion)
  • Fig. 31 Intravenous Market, 2021 - 2033 (USD Billion)